Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic tumors.

Trial Details

NCT ID

NCT06333951

Phase

PHASE1

Sponsor

Amgen

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

Anvumetostat
Carboplatin
Paclitaxel
Pembrolizumab
Pemetrexed
Sotorasib

Locations (sample)

Bakersfield, California, United States|35.37329,-119.01871
Duarte, California, United States|34.13945,-117.97729
Duarte, California, United States|34.13945,-117.97729
Los Angeles, California, United States|34.05223,-118.24368
Orange, California, United States|33.78779,-117.85311

Key Eligibility Criteria

Subprotocol A, B, and C
Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years).
Tumor tissue (formalin-fixed, paraffin-embedded sample) or an archival block must be available. Participants without archived tumor tissue availabl…
Homozygous MTAP-deletion

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →